73898-20-1 Usage
Uses
Used in Pharmaceutical Industry:
Ethanone,1-(4-ethyl-3-hydroxyphenyl)is used as an intermediate in the synthesis of pharmaceuticals for its potential antioxidant and anti-inflammatory properties. Its ability to modulate various biological pathways makes it a promising candidate for the development of new drugs.
Used in Organic Compounds Synthesis:
Ethanone,1-(4-ethyl-3-hydroxyphenyl)is used as a key component in the synthesis of various organic compounds, contributing to the development of new chemical entities with potential applications in different industries.
Used in Research and Development:
Ethanone,1-(4-ethyl-3-hydroxyphenyl)is used as a subject of interest in research and development for its potential antioxidant and anti-inflammatory properties. Its unique chemical structure and properties make it a valuable tool for exploring new therapeutic approaches and applications in the pharmaceutical and healthcare industries.
Check Digit Verification of cas no
The CAS Registry Mumber 73898-20-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,3,8,9 and 8 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 73898-20:
(7*7)+(6*3)+(5*8)+(4*9)+(3*8)+(2*2)+(1*0)=171
171 % 10 = 1
So 73898-20-1 is a valid CAS Registry Number.
73898-20-1Relevant academic research and scientific papers
PHOSPHODIESTERASE 10 INHIBITORS
-
Page/Page column 60, (2008/06/13)
The present invention if directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS
-
Page/Page column 57, (2010/11/28)
The present invention is directed to cinnoline and quinazoline compounds of formula (I) that are PDE10 inhibitors, pharmaceutical compounds containing the same and processes for preparing the same. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like.
